Entera Bio Ltd. Warrants Listed on NASDAQ
Ticker: ENTX · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1638097
| Field | Detail |
|---|---|
| Company | Entera Bio LTD. (ENTX) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: warrants, listing, nasdaq
Related Tickers: ENTX
TL;DR
ENTXW warrants now trading on NASDAQ, strike $5.85.
AI Summary
Entera Bio Ltd. announced on March 4, 2024, that its warrants, exercisable for half an Ordinary Share at $5.85, are listed on NASDAQ under the ticker ENTXW. This filing is a current report (8-K) detailing this information.
Why It Matters
The listing of warrants on NASDAQ provides liquidity and potential trading opportunities for investors holding these instruments.
Risk Assessment
Risk Level: medium — Warrants are derivative instruments with inherent risks related to their exercise price, expiration, and the underlying stock's performance.
Key Numbers
- $5.85 — Warrant Exercise Price (The price at which a warrant holder can purchase half an Ordinary Share.)
Key Players & Entities
- Entera Bio Ltd. (company) — Registrant
- NASDAQ (company) — Stock Exchange
- ENTXW (company) — Warrant Ticker Symbol
- $5.85 (dollar_amount) — Warrant Exercise Price
FAQ
What is the purpose of this 8-K filing?
This 8-K filing serves as a current report to announce the listing of Entera Bio Ltd.'s warrants on NASDAQ.
What is the ticker symbol for Entera Bio Ltd.'s warrants?
The ticker symbol for Entera Bio Ltd.'s warrants is ENTXW.
What is the exercise price for each warrant?
Each warrant is exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary Share.
On which exchange are the warrants listed?
The warrants are listed on NASDAQ.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is March 4, 2024.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-04 08:30:43
Filing Documents
- zk2431079.htm (8-K) — 32KB
- exhibit_99-1.htm (EX-99.1) — 11KB
- image0.jpg (GRAPHIC) — 4KB
- 0001178913-24-000794.txt ( ) — 230KB
- entx-20240304.xsd (EX-101.SCH) — 5KB
- entx-20240304_def.xml (EX-101.DEF) — 18KB
- entx-20240304_lab.xml (EX-101.LAB) — 27KB
- entx-20240304_pre.xml (EX-101.PRE) — 20KB
- zk2431079_htm.xml (XML) — 7KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 4, 2024, Entera Bio Ltd., a company organized under the laws of the State of Israel ("we," "us," "our" or the "Company"), issued a press release announcing that it has regained compliance with Nasdaq's minimum bid price requirement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01. The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated March 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENTERA BIO LTD. Date: March 4, 2024 By: /s/ Miranda Toledano Name: Miranda Toledano Title: Chief Executive Officer